Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus
Authors:
- 3 July 2018
- journal article
- editorial
- Published by Wolters Kluwer Health in Circulation
- Vol. 138 (1) , 7-9
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME TrialDiabetes Care, 2017
- Sodium Glucose Cotransporter-2 Inhibition in Heart FailureCirculation, 2017
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Body weight in adolescence and long-term risk of early heart failure in adulthood among men in SwedenEuropean Heart Journal, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015